{"title":"Sex-specific prolactin disturbance and divergent gonadal hormone correlates in first-episode schizophrenia.","authors":"Anle Pan, Jindong Wang, Jing Liang, Meihong Xiu, Qiang Hu, Shuangli Zhang","doi":"10.1093/ijnp/pyaf068","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hyperprolactinemia and altered prolactin (PRL) levels are well-documented in schizophrenia. However, very few studies have investigated sex-specific differences in the prevalence of PRL disturbances in first-episode patients with schizophrenia. This cross-sectional study investigated sex-specific PRL dysregulation and its interplay with gonadal hormones in first-episode schizophrenia patients.</p><p><strong>Methods: </strong>One hundred eighty-nine first-episode patients (96 males, 93 females) with minimally treated (≤2 weeks) were recruited. PRL levels and gonadal hormones were measured in all participants.</p><p><strong>Results: </strong>We found a significantly higher prevalence of abnormal PRL levels in males compared to females (32.3% vs. 8.6%, χ2 = 16.2, p<.001). Comparative analysis of gonadal hormones between elevated PRL (n = 39) and normal PRL (n = 150) groups demonstrated elevated follicle-stimulating hormone (Z = 2.7, p=.007) and testosterone (Z = 3.7, p<.001) in the hyperprolactinemic group. In the elevated PRL group, PRL positively correlated with progesterone and testosterone, whereas in the normal PRL group, PRL showed positive associations with estradiol and luteinizing hormone, but negative correlations with progesterone.</p><p><strong>Conclusions: </strong>Our findings underscore the complex and sex-specific nature of PRL dysregulation and its association with gonadal hormones in first-episode schizophrenia patients.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ijnp/pyaf068","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Hyperprolactinemia and altered prolactin (PRL) levels are well-documented in schizophrenia. However, very few studies have investigated sex-specific differences in the prevalence of PRL disturbances in first-episode patients with schizophrenia. This cross-sectional study investigated sex-specific PRL dysregulation and its interplay with gonadal hormones in first-episode schizophrenia patients.
Methods: One hundred eighty-nine first-episode patients (96 males, 93 females) with minimally treated (≤2 weeks) were recruited. PRL levels and gonadal hormones were measured in all participants.
Results: We found a significantly higher prevalence of abnormal PRL levels in males compared to females (32.3% vs. 8.6%, χ2 = 16.2, p<.001). Comparative analysis of gonadal hormones between elevated PRL (n = 39) and normal PRL (n = 150) groups demonstrated elevated follicle-stimulating hormone (Z = 2.7, p=.007) and testosterone (Z = 3.7, p<.001) in the hyperprolactinemic group. In the elevated PRL group, PRL positively correlated with progesterone and testosterone, whereas in the normal PRL group, PRL showed positive associations with estradiol and luteinizing hormone, but negative correlations with progesterone.
Conclusions: Our findings underscore the complex and sex-specific nature of PRL dysregulation and its association with gonadal hormones in first-episode schizophrenia patients.
期刊介绍:
The central focus of the journal is on research that advances understanding of existing and new neuropsychopharmacological agents including their mode of action and clinical application or provides insights into the biological basis of psychiatric disorders and thereby advances their pharmacological treatment. Such research may derive from the full spectrum of biological and psychological fields of inquiry encompassing classical and novel techniques in neuropsychopharmacology as well as strategies such as neuroimaging, genetics, psychoneuroendocrinology and neuropsychology.